Vor Bio presents research on patients participating in CGT trials

Vor Bio (VOR) presented novel research evaluating the patient experience and barriers to enrollment and participation in cell and gene therapy, CGT, trials. The data, which was presented at the TANDEM Meetings of ASTCT and CIBMTR, demonstrated the need to improve the process and experience of patients considering and enrolling in CGT trials. Key findings from the data: Educating patients and enrolling them in CGT trials requires more time compared to non-CGT trials due to their complexity and patients’ need for additional reassurance or emotional support. Despite the extra time required to educate patients, this did not prevent any survey participants from offering these trials to patients, underscoring the transformative potential of these treatments. Study respondents reported that patients share many concerns about CGT trials, including the fear of unknown risks of gene editing and caregiver requirements.